Ann-Hunter Van Kirk

Senior Equity Research Analyst Biopharmaceuticals • Bloomberg Intelligence

Ann-Hunter Van Kirk is a Senior Equity Research Analyst at Bloomberg Intelligence covering the Biopharmaceutical sector with a focus on gene editing, animal health, neuroscience, generics, and eyecare companies. A.H. brings a long career of sell-side healthcare equity research experience from prior positions at Barclays, BMO Capital Markets, and Cantor Fitzgerald. Ms. Van Kirk holds a master’s degree from the London School of Economics and two bachelor’s degrees from Southern Methodist University with honors.

Also speaking

Allison Blair

Head of Laboratory • NHS Blood and Transplant

Dorothea Ledergerber

Chief Technical Officer • Tigen Pharma

Bastian Nießing

Group Manager, Automation in Life Sciences • Fraunhofer IPT

Event Info


2022 Spotlight Roundtables

Take a look at the 2022 sample attendee list for Advanced Therapies Europe here.

Pub & Pints RSVP

Let us know you’re planning on attending.